Metraipolis › archive › dc_acdf93ae17d1

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations — Europe PMC PMID:42137592

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42137592
DOI
10.1016/j.omta.2026.201710
License (as archived)
solo-consultazione
Archived
2026-11-05T12:30:19.120Z
SHA-256 of the archived text
1b73953b7957f52afabc00facd6d8cd1d21d76b379eeb7e4b782f42e50869c8b
Stable URL of this page
https://metraipolis.com/documento/dc_acdf93ae17d1

How to cite

A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations — Europe PMC PMID:42137592 — Europe PMC (en), https://europepmc.org/article/MED/42137592 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_acdf93ae17d1 (Metraipolis archive dc_acdf93ae17d1, sha256 1b73953b7957f52afabc00facd6d8cd1d21d76b379eeb7e4b782f42e50869c8b)
BibTeX
@misc{dcacdf93ae17d1,
  title = {A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations — Europe PMC PMID:42137592},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42137592},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_acdf93ae17d1; sha256 1b73953b7957f52afabc00facd6d8cd1d21d76b379eeb7e4b782f42e50869c8b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42137592. Agents can read the archived copy with the MCP tool read_document.